Inhaled Antibiotics Global Market Report 2023

“Inhaled Antibiotics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhaled antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhaled antibiotics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The inhaled antibiotics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product Type: Aerosol or Metered Dose Inhaler; Dry Powder Formulation; Spray; Other Types

• 2) By Application: Pneumonia; Asthma; Bronchitis; Other Applications

• 3) By End-User: Hospitals; Other End Users

• Companies Mentioned: Gilead Sciences Inc; Lupin Limited; Insmed, Inc; Savara Inc; Joincare Pharmaceutical Group Industry Co., Ltd.

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the inhaled antibiotics market are Gilead Sciences Inc., Lupin Limited, Insmed, Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co., Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt Ltd., Precept Pharma Ltd., and Luckys Pharma.

The global inhaled antibiotics market is expected to grow from $1.34 billion in 2022 to $1.45 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The inhaled antibiotics market is expected to grow to $1.92 billion in 2027 at a CAGR of 7.2%.

The inhaled antibiotics market consists of sales of jet nebulizers, ultrasonic nebulizers, mesh inhalers, and soft mist inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Inhaled antibiotics refer to drugs that act as medication for respiratory-related problems. Inhaled antibiotics have enhanced survival and have been used to improve lung function, delay deterioration in lung function, extend time between exacerbations, and improve quality of life.

North America was the largest region in the inhaled antibiotics market in 2022. The regions covered in the inhaled antibiotics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of inhaled antibiotics are aerosol or metered dose inhalers, dry powder formulations, sprays and others. A metered-dose inhaler, or MDI, is a device that is frequently used to provide inhaled respiratory drugs. These are used in various applications such as pneumonia, asthma, bronchitis and others, which are used by hospitals, and others.

The increasing incidence of respiratory diseases is expected to propel the growth of the inhaled antibiotics market going forward. Respiratory disease is a disease that damages the lungs and airways and impairs breathing in people. Inhaled antibiotics enhance lung function, prevent lung function decline, extend the period between exacerbations, and enhance the quality of life in cystic fibrosis patients. For instance, in November 2021, according to stats published by the US bureau of labor statistics, a US-based government agency, there was an increase in employer-reported respiratory illness cases in 2020 at 428,700, up from 10,800 in 2019. The number of incidents of respiratory illness per 10,000 full-time equivalent workers increased from 1.1 in 2019 to 44.0 in 2020. Therefore, an increasing incidence of respiratory diseases drives the inhaled antibiotics market.

Investments in the development of inhaled antibiotics are a key trend gaining popularity in inhaled antibiotics market. Major pharmaceutical companies are investing in the development of inhaled antibiotics to sustain their position in the market. For instance, in December 2021, Enbiotix, a US-based drug development company invested $11 million in the development of antibiotics for lung infections. This funding would help with clinical testing of murepavadin, and ColiFin (inhaled colistimethate sodium) that are used for patients suffering from cystic fibrosis (CF).

In August 2021, Philip Morris International Inc., a US-based Tobacco company, acquired OtiTopic for an undisclosed amount. This acquisition is part of PMI's strategic objective to expand its pipeline of inhaled therapies and respiratory medication delivery by using its expertise, scientific know-how, and inhalation capabilities apart from nicotine. OtiTopic is a US-based respiratory drug development company including inhaled antibotics.

The countries covered in the inhaled antibiotics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The inhaled antibiotics market research report is one of a series of new reports from The Business Research Company that provides inhaled antibiotics market statistics, including inhaled antibiotics industry global market size, regional shares, competitors with an inhaled antibiotics market share, detailed inhaled antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the inhaled antibiotics industry. This inhaled antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.